This volume covers contemporary advances in five important areas of pharmacology and medicinal chemistry including: a comprehensive account of inhibitors of the caspase family of proteolytic enzymes that represent a new class of anti-inflammatory and antiapoptotic agents of potential value in rheumatoid arthritis, and other peripheral and central indications; adoc umented survey of semi-synthetic and totally synthetic antibiotics and anti HIV agents and their sites of interaction; inhibitors of the intracellular enzyme acyl-CoA: cholesterol O-acyltransferase (ACAT) developed for the...
This volume covers contemporary advances in five important areas of pharmacology and medicinal chemistry including: a comprehensive account of inhi...
This volume features accounts of the biological rationale, design and clinical potential of drug molecules; summaries of structure-activity relationships in topical areas of medicinal chemistry and extensive references to the biology, medicinal chemistry and clinical aspects of each topic.
This volume features accounts of the biological rationale, design and clinical potential of drug molecules; summaries of structure-activity relatio...
The perceived lack of drug discovery productivity in recent times has led to much debate in the pharmaceutical/biotechnology industry as escalating R&D costs are not being matched by increased output. Few observers doubt that selecting the right targets, ie those which are critical to disease pathology and are 'druggable', is the best starting point for improved productivity. The seven chapters of this volume describe recent progress towards drugs acting at a range of 'druggable' targets. One chapter addresses kinases, one covers an ion channel, two proteases are featured and three of the...
The perceived lack of drug discovery productivity in recent times has led to much debate in the pharmaceutical/biotechnology industry as escalating R&...
Appropriate selection of biochemical targets is one of the most important drivers of cost effectiveness in the discovery of new medicines. Despite the many advances in genetics, genomics and systems biology, 'validation' of a target is not achieved until therapeutic efficacy is demonstrated by a drug candidate. Volume 46 of this series reviews the medicinal chemistry aimed at six diverse targets from which important new medicines are emerging: * HIV integrase (discovery of the first-in-class inhibitor drug raltegravir) * 11-beta-Hydroxysteroid dehydrogenase (new approach to...
Appropriate selection of biochemical targets is one of the most important drivers of cost effectiveness in the discovery of new medicines. Despite the...
